Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Dermato-Onco2024 | Impact of de novo autoimmune skin toxicities during therapy with ICIs

Yevgeniy Semenov • 8 Nov 2024
Dermato-Onco2024
Skin Cancer Checkpoint Inhibitors

Yevgeniy Semenov, MD, Massachusetts General Hospital, Boston, MA, discusses the impact of de novo autoimmune cutaneous connective tissue disease in patients undergoing anti-PD-(L)1 therapy. Although cutaneous connective tissue disease may emerge during immunotherapy, it was not associated to negative outcomes like increased mortality, and associated toxicities may subside over time, when immunotherapy is no longer administered in patients. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Yevgeniy Semenov

Managing skin toxicities during immune checkpoint inhibitor therapy
8:05
Managing skin toxicities during immune checkpoint inhibitor therapy
Yevgeniy Semenov • 8 Nov 2024
Guidelines for diagnosing skin toxicities during immunotherapy
1:18
Guidelines for diagnosing skin toxicities during immunotherapy
Yevgeniy Semenov • 8 Nov 2024
Correlation between cutaneous immune-related adverse events and OS with immune checkpoint inhibitors
2:45
Correlation between cutaneous immune-related adverse events and OS with immune checkpoint inhibitors
Yevgeniy Semenov • 13 Nov 2021
Risks and outcomes of COVID-19 infection for patients on immunotherapy
1:04
Risks and outcomes of COVID-19 infection for patients on immunotherapy
Yevgeniy Semenov • 13 Nov 2021

Related Videos

Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
2:41
Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
Alexandra Haugh • 30 May 2026
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
1:05
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
James Smithy • 31 May 2026
Optimal timing of ctDNA dynamics to prognosticate ICI efficacy in melanoma
1:26
Optimal timing of ctDNA dynamics to prognosticate ICI efficacy in melanoma
Vincent Ma • 31 May 2026
Phase Ib/II trial of PHP therapy with nivo/rela in metastatic melanoma and liver metastasis
1:42
Phase Ib/II trial of PHP therapy with nivo/rela in metastatic melanoma and liver metastasis
Vincent Ma • 31 May 2026
The content of VJOncology is intended for healthcare professionals